Goldman Sachs Downgrades Watson Pharmaceuticals (WPI) to Neutral
Tweet
Share
E-mailGet Alerts WPI Hot Sheet
Price: $85.73 --0%
Rating Summary:
13 Buy, 4 Hold, 0 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 8 | Down: 5 | New: 26
Rating Summary:
13 Buy, 4 Hold, 0 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 8 | Down: 5 | New: 26
Join SI Premium – FREE
Goldman Sachs downgraded Watson Pharmaceuticals (NYSE: WPI) from Buy to Neutral with a price target of $96.00 (from $100.00).
The firm said they continue to view the stock as a generic holding, that will benefit from Actavis synergies and upcoming product launches. However, this is well understood by investors and they see more upside in other names.
For an analyst ratings summary and ratings history on Watson Pharmaceuticals click here. For more ratings news on Watson Pharmaceuticals click here.
Shares of Watson Pharmaceuticals closed at $87.99 yesterday.
The firm said they continue to view the stock as a generic holding, that will benefit from Actavis synergies and upcoming product launches. However, this is well understood by investors and they see more upside in other names.
For an analyst ratings summary and ratings history on Watson Pharmaceuticals click here. For more ratings news on Watson Pharmaceuticals click here.
Shares of Watson Pharmaceuticals closed at $87.99 yesterday.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Advance Auto Parts (AAP) PT Lowered to $48 at DA Davidson Following 25% Selloff Post Q2 Results
- Deere (DE) PT Raised to $585 at JPMorgan
- Viking Holdings (VIK) PT Raised to $82 at Mizuho
Create E-mail Alert Related Categories
Analyst PT Change, DowngradesSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
